Skip to content
10-Q

Quarterly Report

SPRING PHARMACEUTICAL GROUP, INC.

0001096906-17-000731

← back to feed
Filed
Nov 14, 2017 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2017 · Nov 14, 2017 29.79M sh
Operating Cash Flow Q2 2017 · Sep 30, 2017 $10.74M
Operating Cash Flow Q2 2017 · Sep 30, 2016 $4.94M
Stockholders Equity Q2 2017 · Sep 30, 2017 $97.1M
Stockholders Equity Q2 2017 · Mar 31, 2017 $87.3M
Current Liabilities Q2 2017 · Sep 30, 2017 $1.37M
Current Liabilities Q2 2017 · Mar 31, 2017 $2.99M
Current Assets Q2 2017 · Sep 30, 2017 $22.7M
Current Assets Q2 2017 · Mar 31, 2017 $18.48M
Total Assets Q2 2017 · Sep 30, 2017 $98.47M
Total Assets Q2 2017 · Mar 31, 2017 $90.29M
Capex restated Q2 2017 · Sep 30, 2016 $1.39M
Cash And Equivalents Q2 2017 · Sep 30, 2016 $8.6M
Cash And Equivalents Q2 2017 · Mar 31, 2016 $7.64M
Sga Expense Q2 2017 · Sep 30, 2016 $734.5K
Sga Expense Q2 2017 · Sep 30, 2016 $1.58M
Rd Expense Q2 2017 · Sep 30, 2016 $405.74K
Rd Expense Q2 2017 · Sep 30, 2016 $474.9K
Net Income Q2 2017 · Sep 30, 2016 $2M
Net Income Q2 2017 · Sep 30, 2016 $3.57M
Operating Income Q2 2017 · Sep 30, 2016 $2.63M
Operating Income Q2 2017 · Sep 30, 2016 $4.77M
Gross Profit Q2 2017 · Sep 30, 2016 $4.58M
Gross Profit Q2 2017 · Sep 30, 2016 $8.38M
Revenue Q2 2017 · Sep 30, 2016 $11.59M
Revenue Q2 2017 · Sep 30, 2016 $21.31M